Skip to Content

Medigene AG MDGEF

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Medigene AG is a Germany based biotechnology company. Along with its subsidiaries, the company is primarily engaged in developing immunotherapies to target various forms and stages of cancer with candidates in clinical and pre-clinical development. The group is focused on the development of personalized T cell-based therapies. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy, DC vaccines, and T-cell-specific monoclonal antibodies. The group operates in the United States, Europe, and Other countries, of which majority of the revenue is derived from operations in the United States.

Contact
Lochhamer Strasse 11, Martinsried
Planegg, 82152, Germany
T +49 892000330
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Jun 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type
Employees 136